<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02797522</url>
  </required_header>
  <id_info>
    <org_study_id>ARC5211001</org_study_id>
    <nct_id>NCT02797522</nct_id>
  </id_info>
  <brief_title>A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)</brief_title>
  <official_title>A Sequential Phase 1a/1b Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ARC-521 in Normal Adult Volunteers and Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrowhead Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Arrowhead Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Normal healthy volunteer (NHV) participants will enroll sequentially into a total of 6
      escalating dose levels (6 subjects per dose level), randomized to receive a single dose of
      ARC-521 Injection or placebo. The maximum study duration for NHVs is approximately 21 weeks.

      Hepatitis B e Antigen (HBeAg)-negative participants with (CHB) will enroll sequentially into
      3 dose levels (8 patients per dose level) to receive multiple doses of open label ARC-521
      Injection. For each CHB participant the maximum study duration is approximately 37 weeks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1a/1b multicenter dose-escalation study of ARC-521 Injection in normal healthy
      volunteers and patients with CHB. Eligible participants who have signed an Ethics Committee
      (EC)/Institutional Review Board (IRB) approved informed consent form and have met all of the
      protocol eligibility criteria.

      Patients will undergo the following evaluations at regular intervals during the study:
      medical history, physical examinations, vital sign measurements (blood pressure, heart rate,
      respiratory rate, and temperature), weight, adverse events assessment (AEs), concomitant
      medications/therapies assessment, electrocardiograms (ECGs), telemetry [NHVs only], measures
      of hepatic fibrosis [CHBs only], blood sample collection for hematology, coagulation,
      chemistry, Pharmacokinetics (PK) [NHVs only], metabolic analysis [NHVs only], exploratory
      Pharmacodynamic (PD) measures, urinalysis, hepatitis B virus (HBV) serology, immunogenicity,
      Follicle Stimulating Hormone (FSH) testing (post-menopausal females) and pregnancy testing
      for females of childbearing potential. Clinically significant changes including AEs will be
      followed until resolution, until the condition stabilizes, until the event is otherwise
      explained, or until the patient is lost to follow-up. Prior to enrollment there is a 60 day
      screening period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company decision to discontinue trial
  </why_stopped>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events (TEAEs): Healthy Volunteers</measure>
    <time_frame>From first dose of study drug through Day 29 (± 1 day)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. A serious AE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With TEAEs: CHB Participants</measure>
    <time_frame>From first dose of study drug through Day 142 (± 3 days)</time_frame>
    <description>An AE is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. A serious AE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0-24 Hours (AUC0-24), Healthy Volunteers</measure>
    <time_frame>Through 48 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast), Healthy Volunteers</measure>
    <time_frame>Through 48 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf), Healthy Volunteers</measure>
    <time_frame>Through 48 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-521 Injection: Maximum Observed Plasma Concentration (Cmax), Healthy Volunteers</measure>
    <time_frame>Through 48 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-521 Injection: Clearance (CL), Healthy Volunteers</measure>
    <time_frame>Through 48 hrs post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-521 Injection: Apparent Volume of Distribution (V), Healthy Volunteers</measure>
    <time_frame>Through 48 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-521 Injection: Terminal Elimination Rate Constant (Kel), Healthy Volunteers</measure>
    <time_frame>Through 48 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of ARC-521 Injection: Terminal Elimination Half-Life (t1/2), Healthy Volunteers</measure>
    <time_frame>Through 48 hours post-dose on Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change Over Time in Viral Antigens and DNA in CHB Participants as a Measure of Activity of ARC-521 Injection</measure>
    <time_frame>Baseline to Day 142</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in Cytokine Levels After Single and Multiple Doses of ARC-521 Injection</measure>
    <time_frame>Through 24 hours post-dose (Day 1 for NHVs, and Days 1, 29 &amp; 57 for CHB participants)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change Over Time in Complement Levels After Single and Multiple Doses of ARC-521 Injection</measure>
    <time_frame>Through 24 hours post-dose (Day 1 for NHVs, and Days 1, 29 &amp; 57 for CHB participants)</time_frame>
  </secondary_outcome>
  <number_of_arms>11</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>NHV Participants: Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHV Participants: Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHV Participants: Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHV Participants: Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHV Participants: Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHV Participants: Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NHV Participants: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHB Participants: Cohort 3b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual nucleoside analog (NUC) therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHB Participants: Cohort 4b</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHB Participants: Cohort 3c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHB Participants: Cohort 4c</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARC-521 Injection</intervention_name>
    <arm_group_label>CHB Participants: Cohort 3b</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 3c</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 4b</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 4c</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 1</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 2</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 3</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 4</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 5</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>0.9% normal saline</description>
    <arm_group_label>NHV Participants: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antihistamine</intervention_name>
    <description>Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with an oral antihistamine, selected by the investigator from the list of approved antihistamines that is available in that country. Approved antihistamines are: diphenhydramine 50 mg by mouth (PO), chlorpheniramine 8 mg PO, or hydroxyzine 50 mg PO.</description>
    <arm_group_label>CHB Participants: Cohort 3b</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 3c</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 4b</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 4c</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 1</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 2</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 3</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 4</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 5</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 6</arm_group_label>
    <arm_group_label>NHV Participants: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acetaminophen</intervention_name>
    <description>Approximately two hours prior to ARC-521 or placebo administration, participants will be pre-treated with acetaminophen (500 - 1000 mg PO, per local strength availability).</description>
    <arm_group_label>CHB Participants: Cohort 3b</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 3c</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 4b</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 4c</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 1</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 2</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 3</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 4</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 5</arm_group_label>
    <arm_group_label>NHV Participants: Cohort 6</arm_group_label>
    <arm_group_label>NHV Participants: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>entecavir</intervention_name>
    <description>Participants take entecavir OR tenofovir daily throughout the study.</description>
    <arm_group_label>CHB Participants: Cohort 3c</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 4c</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenofovir</intervention_name>
    <description>Participants take entecavir OR tenofovir daily throughout the study.</description>
    <arm_group_label>CHB Participants: Cohort 3c</arm_group_label>
    <arm_group_label>CHB Participants: Cohort 4c</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, 18 to 55 years of age inclusive (NHVs) or 18-65 years of age inclusive
             (CHBs), at the time of informed consent

          -  Able to provide written informed consent prior to the performance of any study
             specific procedures

          -  Body mass index (BMI) between 19.0 and 35.0 kg/m2, inclusive

          -  A 12-lead ECG at Screening and pre-dose assessment that, in the opinion of the
             investigator, has no abnormalities that compromise participant's safety in this study

          -  Must use 2 effective methods of contraception (double barrier contraception or
             hormonal contraceptive along with a barrier contraceptive (both male and female
             partners)

          -  Have suitable venous access for blood sampling

          -  No abnormal finding of clinical relevance at the Screening evaluation (NHVs only)

          -  Have a diagnosis of HbeAg-negative chronic HBV infection (CHB patients only)

          -  Treatment-naive or currently on entecavir/tenofovir for 6 months or longer

        Exclusion Criteria:

          -  Pregnant or lactating

          -  Acute signs of hepatitis/other infection at Screening or at baseline

          -  Use within last 14 days or anticipated requirement for anticoagulants, systemic
             corticosteroids, immunomodulators, or immunosuppressants

          -  Use of prescription medication within 14 days prior to study treatment that in the
             opinion of the PI or the Sponsor would interfere with study conduct.

          -  Known diagnosis of non-alcoholic steatohepatitis [NHVs only] or familial
             hypercholesterolemia

          -  Taking interferon alpha (INFalpha) within 6 months of screening [CHBs only]

          -  History of poorly controlled autoimmune disease or history of autoimmune hepatitis

          -  Human immunodeficiency virus (HIV) infection

          -  Seropositive for HBV (NHVs only) or hepatitis C virus (HCV), and/or history of delta
             virus hepatitis

          -  Hypertension defined as blood pressure &gt; 170/100 mmHg at screening [NHVs only]

          -  A history of cardiac rhythm disturbances

          -  Family history of congenital long QT syndrome, Brugada syndrome or unexplained sudden
             cardiac death

          -  Symptomatic heart failure, unstable angina, myocardial infarction, severe
             cardiovascular disease within 6 months prior to study entry

          -  History of malignancy within the last 5 years except for adequately treated basal cell
             carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical
             cancer

          -  History of major surgery within 3 months of Screening

          -  Regular use of alcohol within one month prior to the Screening visit (more than
             fourteen units of alcohol per week)

          -  Evidence of severe systemic acute inflammation, sepsis, or hemolysis [NHVs only]

          -  Use within 3 months of illicit drugs (cocaine, phencyclidine [PCP],
             3,4-methylenedioxymethamphetamine [MDMA], others) or positive test for drugs of abuse
             at screening.

          -  History of allergy to bee venom or history of severe hypersensitivity reaction, such
             as anaphylaxis

          -  Use of an investigational agent or device within 30 days prior to dosing or current
             participation in an investigational study

          -  Clinically significant history of any alcoholic liver disease, cirrhosis, Wilson's
             disease, hemochromatosis, or alpha-1 antitrypsin deficiency, liver or kidney disease

          -  Clinically significant history/presence of poorly controlled or decompensated
             neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic,
             psychiatric, metabolic, or other uncontrolled systemic disease

          -  Blood donation (500 mL) within 7 days prior to study treatment administration [NHVs
             only]

          -  History of fever (&gt;38.0ºC/100.4ºF) within 2 weeks of Screening [NHVs only]

          -  Any concomitant medical or psychiatric condition or social situation that impacts
             compliance or involves additional safety risk

          -  History of coagulopathy (including deep vein thrombosis and pulmonary embolism) or
             stroke within 6 months of baseline, and/or concurrent anticoagulant medication(s)

          -  Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Auckland Clinical Studies Ltd</name>
      <address>
        <city>Grafton</city>
        <state>Auckland</state>
        <zip>1011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2016</study_first_posted>
  <results_first_submitted>January 10, 2018</results_first_submitted>
  <results_first_submitted_qc>January 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2018</results_first_posted>
  <last_update_submitted>January 10, 2018</last_update_submitted>
  <last_update_submitted_qc>January 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Histamine Antagonists</mesh_term>
    <mesh_term>Histamine H1 Antagonists</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NHV Participants: Cohort 1</title>
          <description>Normal healthy volunteer (NHV) participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
        </group>
        <group group_id="P2">
          <title>NHV Participants: Cohort 2</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
        </group>
        <group group_id="P3">
          <title>NHV Participants: Cohort 3</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
        </group>
        <group group_id="P4">
          <title>NHV Participants: Cohort 4</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
        </group>
        <group group_id="P5">
          <title>NHV Participants: Cohort 5</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
        </group>
        <group group_id="P6">
          <title>NHV Participants: Cohort 6</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
        </group>
        <group group_id="P7">
          <title>NHV Participants: Placebo</title>
          <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
        </group>
        <group group_id="P8">
          <title>CHB Participants: Cohort 3b</title>
          <description>Treatment-naive participants with chronic hepatitis B (CHB) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual nucleoside analog (NUC) therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
        </group>
        <group group_id="P9">
          <title>CHB Participants: Cohort 4b</title>
          <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
        </group>
        <group group_id="P10">
          <title>CHB Participants: Cohort 3c</title>
          <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.</description>
        </group>
        <group group_id="P11">
          <title>CHB Participants: Cohort 4c</title>
          <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="4"/>
                <participants group_id="P7" count="12"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study Terminated by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="4"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="4"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NHV Participants: Cohort 1</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
        </group>
        <group group_id="B2">
          <title>NHV Participants: Cohort 2</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
        </group>
        <group group_id="B3">
          <title>NHV Participants: Cohort 3</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
        </group>
        <group group_id="B4">
          <title>NHV Participants: Cohort 4</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
        </group>
        <group group_id="B5">
          <title>NHV Participants: Cohort 5</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
        </group>
        <group group_id="B6">
          <title>NHV Participants: Cohort 6</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
        </group>
        <group group_id="B7">
          <title>NHV Participants: Placebo</title>
          <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
        </group>
        <group group_id="B8">
          <title>CHB Participants: Cohort 3b</title>
          <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
        </group>
        <group group_id="B9">
          <title>CHB Participants: Cohort 4b</title>
          <description>Treatment-naive participants with CHB administered 3 doses of ARC-521Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
        </group>
        <group group_id="B10">
          <title>CHB Participants: Cohort 3c</title>
          <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.</description>
        </group>
        <group group_id="B11">
          <title>CHB Participants: Cohort 4c</title>
          <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="4"/>
            <count group_id="B6" value="4"/>
            <count group_id="B7" value="12"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="2"/>
            <count group_id="B10" value="4"/>
            <count group_id="B11" value="1"/>
            <count group_id="B12" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="8.26"/>
                    <measurement group_id="B2" value="27.8" spread="10.90"/>
                    <measurement group_id="B3" value="23.3" spread="3.30"/>
                    <measurement group_id="B4" value="22.5" spread="1.29"/>
                    <measurement group_id="B5" value="22.3" spread="3.59"/>
                    <measurement group_id="B6" value="23.5" spread="4.04"/>
                    <measurement group_id="B7" value="28.3" spread="5.69"/>
                    <measurement group_id="B8" value="46.3" spread="10.63"/>
                    <measurement group_id="B9" value="44.5" spread="14.85"/>
                    <measurement group_id="B10" value="44.3" spread="3.69"/>
                    <measurement group_id="B11" value="36.0" spread="NA">1 participant in cohort</measurement>
                    <measurement group_id="B12" value="30.0" spread="8.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="4"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs): Healthy Volunteers</title>
        <description>An adverse event (AE) is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. A serious AE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
        <time_frame>From first dose of study drug through Day 29 (± 1 day)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events (TEAEs): Healthy Volunteers</title>
          <description>An adverse event (AE) is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. A serious AE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;/= 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 1 Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 1 Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 1 Related Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With TEAEs: CHB Participants</title>
        <description>An AE is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. A serious AE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
        <time_frame>From first dose of study drug through Day 142 (± 3 days)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CHB Participants: Cohort 3b</title>
            <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
          </group>
          <group group_id="O2">
            <title>CHB Participants: Cohort 4b</title>
            <description>Treatment-naive participants with CHB administered 3 doses of ARC-521Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
          </group>
          <group group_id="O3">
            <title>CHB Participants: Cohort 3c</title>
            <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CHB Participants: Cohort 4c</title>
            <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With TEAEs: CHB Participants</title>
          <description>An AE is any untoward medical occurrence which does not necessarily have a causal relationship with this treatment. A serious AE is any AE that: results in death; is life-threatening; requires inpatient hospitalization or prolongation of an existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or is a medically important event or reaction.Events were categorized as mild, moderate or severe. TEAEs were defined as all AEs starting or worsening after commencement of treatment with investigational product. A treatment-related TEAE was one whose relationship to treatment was noted as unlikely, possibly, or probably related.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&gt;/= 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 1 Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 1 Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;/= 1 Related Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0-24 Hours (AUC0-24), Healthy Volunteers</title>
        <time_frame>Through 48 hours post-dose on Day 1</time_frame>
        <population>Analysis was not planned or conducted per statistical analysis plan (SAP) due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0-24 Hours (AUC0-24), Healthy Volunteers</title>
          <population>Analysis was not planned or conducted per statistical analysis plan (SAP) due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast), Healthy Volunteers</title>
        <time_frame>Through 48 hours post-dose on Day 1</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0 to the Last Quantifiable Plasma Concentration (AUClast), Healthy Volunteers</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf), Healthy Volunteers</title>
        <time_frame>Through 48 hours post-dose on Day 1</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-521 Injection: Area Under the Plasma-Concentration-Time Curve From Time 0 Extrapolated to Infinity (AUCinf), Healthy Volunteers</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-521 Injection: Maximum Observed Plasma Concentration (Cmax), Healthy Volunteers</title>
        <time_frame>Through 48 hours post-dose on Day 1</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-521 Injection: Maximum Observed Plasma Concentration (Cmax), Healthy Volunteers</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-521 Injection: Clearance (CL), Healthy Volunteers</title>
        <time_frame>Through 48 hrs post-dose on Day 1</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-521 Injection: Clearance (CL), Healthy Volunteers</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-521 Injection: Apparent Volume of Distribution (V), Healthy Volunteers</title>
        <time_frame>Through 48 hours post-dose on Day 1</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-521 Injection: Apparent Volume of Distribution (V), Healthy Volunteers</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-521 Injection: Terminal Elimination Rate Constant (Kel), Healthy Volunteers</title>
        <time_frame>Through 48 hours post-dose on Day 1</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-521 Injection: Terminal Elimination Rate Constant (Kel), Healthy Volunteers</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics of ARC-521 Injection: Terminal Elimination Half-Life (t1/2), Healthy Volunteers</title>
        <time_frame>Through 48 hours post-dose on Day 1</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of ARC-521 Injection: Terminal Elimination Half-Life (t1/2), Healthy Volunteers</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change Over Time in Viral Antigens and DNA in CHB Participants as a Measure of Activity of ARC-521 Injection</title>
        <time_frame>Baseline to Day 142</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>CHB Participants: Cohort 3b</title>
            <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
          </group>
          <group group_id="O2">
            <title>CHB Participants: Cohort 4b</title>
            <description>Treatment-naive participants with CHB administered 3 doses of ARC-521Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
          </group>
          <group group_id="O3">
            <title>CHB Participants: Cohort 3c</title>
            <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CHB Participants: Cohort 4c</title>
            <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Over Time in Viral Antigens and DNA in CHB Participants as a Measure of Activity of ARC-521 Injection</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Over Time in Cytokine Levels After Single and Multiple Doses of ARC-521 Injection</title>
        <time_frame>Through 24 hours post-dose (Day 1 for NHVs, and Days 1, 29 &amp; 57 for CHB participants)</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
          <group group_id="O8">
            <title>CHB Participants: Cohort 3b</title>
            <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
          </group>
          <group group_id="O9">
            <title>CHB Participants: Cohort 4b</title>
            <description>Treatment-naive participants with CHB administered 3 doses of ARC-521Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
          </group>
          <group group_id="O10">
            <title>CHB Participants: Cohort 3c</title>
            <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>CHB Participants: Cohort 4c</title>
            <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Over Time in Cytokine Levels After Single and Multiple Doses of ARC-521 Injection</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change Over Time in Complement Levels After Single and Multiple Doses of ARC-521 Injection</title>
        <time_frame>Through 24 hours post-dose (Day 1 for NHVs, and Days 1, 29 &amp; 57 for CHB participants)</time_frame>
        <population>Analysis was not planned or conducted per SAP due to study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>NHV Participants: Cohort 1</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
          </group>
          <group group_id="O2">
            <title>NHV Participants: Cohort 2</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
          </group>
          <group group_id="O3">
            <title>NHV Participants: Cohort 3</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
          </group>
          <group group_id="O4">
            <title>NHV Participants: Cohort 4</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
          </group>
          <group group_id="O5">
            <title>NHV Participants: Cohort 5</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
          </group>
          <group group_id="O6">
            <title>NHV Participants: Cohort 6</title>
            <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
          </group>
          <group group_id="O7">
            <title>NHV Participants: Placebo</title>
            <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
          </group>
          <group group_id="O8">
            <title>CHB Participants: Cohort 3b</title>
            <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
          </group>
          <group group_id="O9">
            <title>CHB Participants: Cohort 4b</title>
            <description>Treatment-naive participants with CHB administered 3 doses of ARC-521Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
          </group>
          <group group_id="O10">
            <title>CHB Participants: Cohort 3c</title>
            <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.</description>
          </group>
          <group group_id="O11">
            <title>CHB Participants: Cohort 4c</title>
            <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change Over Time in Complement Levels After Single and Multiple Doses of ARC-521 Injection</title>
          <population>Analysis was not planned or conducted per SAP due to study termination.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>NHV: from first dose of study drug through Day 29 (± 1 days); CHB participants:from first dose of study drug through Day 142 (± 3 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NHV Participants: Cohort 1</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 0.6 mg/kg.</description>
        </group>
        <group group_id="E2">
          <title>NHV Participants: Cohort 2</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 1 mg/kg.</description>
        </group>
        <group group_id="E3">
          <title>NHV Participants: Cohort 3</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 2 mg/kg.</description>
        </group>
        <group group_id="E4">
          <title>NHV Participants: Cohort 4</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 4 mg/kg.</description>
        </group>
        <group group_id="E5">
          <title>NHV Participants: Cohort 5</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 5 mg/kg.</description>
        </group>
        <group group_id="E6">
          <title>NHV Participants: Cohort 6</title>
          <description>NHV participants administered a single dose of ARC-521 Injection at a dose of 6 mg/kg.</description>
        </group>
        <group group_id="E7">
          <title>NHV Participants: Placebo</title>
          <description>NHV participants administered 0.9% normal saline to match ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg.</description>
        </group>
        <group group_id="E8">
          <title>CHB Participants: Cohort 3b</title>
          <description>Treatment-naive participants with CHB administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
        </group>
        <group group_id="E9">
          <title>CHB Participants: Cohort 4b</title>
          <description>Treatment-naive participants with CHB administered 3 doses of ARC-521Injection at 4 mg/kg once every 4 weeks. Participants are treatment-naive if they have not been on continual NUC therapy (any NUC) for at least 6 months prior to screening (or have never been on NUCs).</description>
        </group>
        <group group_id="E10">
          <title>CHB Participants: Cohort 3c</title>
          <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 2 mg/kg once every 4 weeks.</description>
        </group>
        <group group_id="E11">
          <title>CHB Participants: Cohort 4c</title>
          <description>Participants with CHB currently on NUCs (entecavir or tenofovir for at least 6 months) administered 3 doses of ARC-521 Injection at 4 mg/kg once every 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear deformity acquired</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Sensitivity of teeth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site bruise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Catheter site pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Catheter site swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The ARC-521 Injection development program was terminated early for regulatory and business reasons secondary to findings occurring in a non-clinical toxicology study. Program termination was not due to safety findings in humans.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Chief Operating Officer</name_or_title>
      <organization>Arrowhead Pharmaceuticals, Inc.</organization>
      <phone>626-304-3400</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

